EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?

Maria Cecília Mathias-Machado, Victor Hugo Fonseca de Jesus, Alexandre Jácome, Mauro Daniel Donadio iD, Marcelo Porfirio Sunagua Aruquipa, João Fogacci, Renato Guerino Cunha, Leonard Medeiros da Silva, Renata D'Alpino Peixoto iD

Cancers · 05.02.2024 · 16 (3) · 679

DOI: 10.3390/cancers16030679 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.02.2024. Verfasst von Maria Cecília Mathias-Machado und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Medical Oncology, Oncoclínicas, São Paulo 04538-132, Brazil. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) remains a formidable global health challenge, ranking among the top-five causes of cancer-related deaths worldwide. The majority of patients face advanced stages at diagnosis, with a mere 6% five-year survival rate. First-line treatment for metastatic GC typically involves a fluoropyrimidine and platinum agent combination; yet, predictive molecular markers have proven elusive. This review navigates the evolving landscape of GC biomarkers, with a specific focus on Claudin 18.2 (CLDN18.2) as an emerging and promising target. Recent phase III trials have unveiled the efficacy of Zolbetuximab, a CLDN18.2-targeting antibody, in combination with oxaliplatin-based chemotherapy for CLDN18.2-positive metastatic GC. As this novel therapeutic avenue unfolds, understanding the nuanced decision making regarding the selection of anti-CLDN18.2 therapies over other targeted agents in metastatic GC becomes crucial. This manuscript reviews the evolving role of CLDN18.2 as a biomarker in GC and explores the current status of CLDN18.2-targeting agents in clinical development. The aim is to provide concise insights into the potential of CLDN18.2 as a therapeutic target and guide future clinical decisions in the management of metastatic GC.

Schlagwörter

Stichwörter der Autor:innen

biomarkerscancergastric cancertreatment

Autor:innen und Institutionen

  • Division of Gastrointestinal Medical Oncology, Oncoclínicas, São Paulo 04538-132, Brazil.
  • Division of Gastrointestinal Medical Oncology, Oncoclínicas, Florianópolis 88015-020, Brazil.
  • Division of Gastrointestinal Medical Oncology, Oncoclínicas, Belo Horizonte 30360-680, Brazil.
  • Division of Gastrointestinal Medical Oncology, Oncoclínicas, Rio de Janeiro 22775-003, Brazil.
  • Cellular Therapy Program, Division of Hematology, Oncoclínicas, São Paulo 04538-132, Brazil.
  • Oncoclinicas Prescision Medicine, Oncoclínicas, São Paulo 04513-020, Brazil.

ORCID-Profile: Mauro Daniel Donadio, Renata D'Alpino Peixoto

Zitieren

APA

Mathias-Machado, M. C., de Jesus, V. H. F., Jácome, A., Donadio, M. D., Aruquipa, M. P. S., Fogacci, J., Cunha, R. G., da Silva, L. M., & Peixoto, R. D. (2024). Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?. Cancers, 16(3), 679. https://doi.org/10.3390/cancers16030679

Vancouver

Mathias-Machado MC, de Jesus VHF, Jácome A, Donadio MD, Aruquipa MPS, Fogacci J, et al. Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?. Cancers. 2024;16(3):679. doi:10.3390/cancers16030679

BibTeX
@article{MathiasMachado2024,
  author = {Mathias-Machado, Maria Cecília and de Jesus, Victor Hugo Fonseca and Jácome, Alexandre and Donadio, Mauro Daniel and Aruquipa, Marcelo Porfirio Sunagua and Fogacci, João and Cunha, Renato Guerino and da Silva, Leonard Medeiros and Peixoto, Renata D'Alpino},
  title = {Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {3},
  pages = {679},
  doi = {10.3390/cancers16030679}
}
Kostenlos starten →